DCT

1:26-cv-00856

MyoKardia Inc v. MSN Laboratories Pvt Ltd

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 1:26-cv-00856, D. Del., 07/14/2026
  • Venue Allegations: Venue is alleged to be proper for MSN Pharmaceuticals Inc. as it is a Delaware corporation and for MSN Laboratories Private Limited as it is subject to personal jurisdiction in the district.
  • Core Dispute: Plaintiffs allege that Defendants' filing of an Abbreviated New Drug Application (ANDA) to market a generic version of Plaintiffs' Camzyos® (mavacamten) drug product constitutes infringement of two U.S. patents.
  • Technical Context: The technology involves pyrimidinedione compounds, specifically the cardiac myosin inhibitor mavacamten, used for treating obstructive hypertrophic cardiomyopathy (HCM).
  • Key Procedural History: The lawsuit was initiated under the Hatch-Waxman Act following Plaintiffs' receipt of a notice letter from MSN, dated June 9, 2026, which included a Paragraph IV certification. This certification asserts that the patents-in-suit are invalid, unenforceable, and/or will not be infringed by MSN's proposed generic product. The complaint was filed within the 45-day statutory window, triggering an automatic 30-month stay on the FDA's approval of MSN's ANDA.

Case Timeline

Date Event
2013-06-21 Earliest Priority Date for RE'050 and '883 Patents
2017-03-07 U.S. Patent No. 9,585,883 Issues
2024-07-23 U.S. Reissue Patent No. 50,050 Issues
2026-06-09 MSN sends Notice Letter to Plaintiffs
2026-07-14 Complaint Filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Reissue Patent No. 50,050 - "Pyrimidinedione Compounds"

  • Patent Identification: U.S. Reissue Patent No. 50,050, entitled "Pyrimidinedione Compounds," issued on July 23, 2024 Compl. ¶28

The Invention Explained

  • Problem Addressed: The patent addresses the limitations of existing medical therapies for hypertrophic cardiomyopathy (HCM), which primarily treat symptoms rather than the underlying cause of the disease-dysfunction in the sarcomere, the heart's functional unit '883 Patent, col. 2:1-16
  • The Patented Solution: The invention provides novel pyrimidine dione compounds, including mavacamten, that act as cardiac myosin inhibitors '883 Patent, abstract These compounds are described as reducing excess contractility by stabilizing a specific conformation of beta cardiac myosin, thereby decreasing the proportion of myosin molecules available for the "powerstroke" portion of the muscle contraction cycle '883 Patent, col. 3:24-34
  • Technical Importance: This technology represents a therapeutic approach aimed at the fundamental mechanics of HCM, offering a potential disease-modifying treatment rather than purely symptomatic relief '883 Patent, col. 2:1-16

Key Claims at a Glance

  • The complaint asserts infringement of at least claim 20 of the RE'050 patent Compl. ¶31 Compl. ¶35 Compl. ¶39
  • The complaint alleges that the RE'050 patent claims recite, inter alia, a series of specifically defined compounds, including mavacamten Compl. ¶30 The full text of the asserted claim is not provided in the complaint.

U.S. Patent No. 9,585,883 - "Pyrimidinedione Compounds"

  • Patent Identification: U.S. Patent No. 9,585,883, entitled "Pyrimidinedione Compounds," issued on March 7, 2017 Compl. ¶48

The Invention Explained

  • Problem Addressed: As with the RE'050 patent, the '883 patent addresses the lack of medical therapies that treat the root cause of HCM, noting that existing agents are variably effective and do not carry labeled indications for the disease '883 Patent, col. 2:1-16
  • The Patented Solution: The patent discloses methods of using pyrimidinedione compounds, such as mavacamten, to treat HCM '883 Patent, col. 1:44-51 By inhibiting cardiac myosin, these methods aim to reduce hypercontractility and improve cardiac relaxation, directly targeting the sarcomere dysfunction central to the disease '883 Patent, col. 3:24-34 '883 Patent, abstract
  • Technical Importance: The patented methods provide a new therapeutic strategy for HCM by targeting the biomechanical basis of the disease, moving beyond simple symptom management '883 Patent, col. 2:17-22

Key Claims at a Glance

  • The complaint asserts infringement of at least claim 18 of the '883 patent Compl. ¶51 Compl. ¶54-55
  • The complaint alleges that the '883 patent claims recite, inter alia, a method of treating hypertrophic cardiomyopathy (HCM), comprising administering to a subject in need thereof an effective amount of a compound, including mavacamten Compl. ¶50 The full text of the asserted claim is not provided in the complaint, but its essential elements are described as:
    • A method of treating hypertrophic cardiomyopathy (HCM)
    • comprising administering to a subject in need thereof
    • an effective amount of at least one of a series of compounds, including mavacamten.

III. The Accused Instrumentality

Product Identification

  • The accused instrumentality is MSN's proposed generic version of Camzyos® (mavacamten) capsules, for which it has filed ANDA No. 221705 with the FDA Compl. ¶2 Compl. ¶3 The ANDA seeks approval for 2.5 mg, 5 mg, 10 mg, and 15 mg dosage forms Compl. ¶3

Functionality and Market Context

  • The accused product contains mavacamten as its active pharmaceutical ingredient Compl. ¶25 Mavacamten is identified as a cardiac myosin inhibitor used for the treatment of adults with obstructive hypertrophic cardiomyopathy Compl. ¶25 The complaint alleges that MSN's ANDA Product is a generic version of Plaintiffs' branded drug, Camzyos®, and that MSN intends to manufacture, import, and sell this product in the U.S. upon receiving FDA approval Compl. ¶16 Compl. ¶20 Compl. ¶26

IV. Analysis of Infringement Allegations

No probative visual evidence provided in complaint.

The complaint does not provide element-by-element infringement allegations or claim charts. The infringement theories are summarized below in prose.

  • RE'050 Patent Infringement Theory: The complaint alleges that MSN's submission of its ANDA constitutes a technical act of infringement of the RE'050 patent under 35 U.S.C. § 271(e)(2)(A) Compl. ¶37 The basis for this allegation is that MSN's proposed product contains mavacamten, a compound allegedly covered by at least claim 20 of the RE'050 patent Compl. ¶30 Compl. ¶35 The complaint further alleges that the future commercial manufacture, use, or sale of the product would constitute direct infringement Compl. ¶39

  • '883 Patent Infringement Theory: The complaint alleges that the use of MSN's ANDA product as directed by its proposed labeling would infringe at least claim 18 of the '883 patent, a method-of-use claim Compl. ¶55 The act of submitting the ANDA is alleged to be an act of infringement under 35 U.S.C. § 271(e)(2)(A) Compl. ¶57 The complaint further alleges that upon approval, MSN will actively induce infringement by marketing the product with a label that instructs users to administer it in an infringing manner for the treatment of HCM Compl. ¶59

  • Identified Points of Contention:

    • Validity: Since MSN filed a Paragraph IV certification, a central dispute will be whether Defendants can prove by clear and convincing evidence that the asserted claims of the RE'050 and '883 patents are invalid as anticipated or obvious Compl. ¶33 Compl. ¶53
    • Infringement Scope (Method Claim): For the '883 patent, a likely point of contention will be whether the instructions on MSN's proposed product label direct users to perform every step of the patented method of treatment. The analysis will focus on the specific language of the label compared to the limitations of claim 18.
    • Reissue Recapture: As the RE'050 patent is a reissue, its validity may be challenged under the doctrine of recapture, which raises the question of whether the asserted claims attempt to reclaim subject matter that was surrendered during the prosecution of the original patent.

V. Key Claim Terms for Construction

The complaint does not provide the full language of the asserted claims. Based on the complaint's description of the patents and the technological context, the following terms may be central to the dispute.

  • The Term: "treating hypertrophic cardiomyopathy (HCM)" (from the '883 patent)

    • Context and Importance: This term defines the scope of the asserted method-of-use claim. The parties will likely dispute what specific actions, outcomes, or patient populations are encompassed by "treating" HCM. The infringement analysis for the '883 patent will depend on whether the actions directed by the accused product's label fall within the court's construction of this term.
    • Intrinsic Evidence for Interpretation:
      • Evidence for a Broader Interpretation: The specification describes ameliorating a wide range of "pathology, injury, condition, or symptom," including any "objective or subjective parameter such as abatement; remission; [or] diminishing of symptoms" '883 Patent, col. 5:50-58 This language may support a broad definition covering any beneficial effect.
      • Evidence for a Narrower Interpretation: The background section focuses on specific clinical burdens, such as "exertional dyspnea" and symptoms related to "left ventricular outflow obstruction" '883 Patent, col. 1:47-51 A party could argue that "treating" should be limited to addressing these specifically identified symptoms or conditions.

  • The Term: "an effective amount" (from the '883 patent)

    • Context and Importance: The definition of an "effective amount" is critical for determining whether the dosage instructions on the accused product's label lead to infringement. Practitioners may focus on this term because the patent discloses specific dosage ranges that could be used to argue for a narrower or broader interpretation.
    • Intrinsic Evidence for Interpretation:
      • Evidence for a Broader Interpretation: The specification provides a general definition: "an appropriate dosage level will generally be about 0.001 to 100 mg per kg patient body weight per day" '883 Patent, col. 18:66-col. 19:1 This wide range could support a broad interpretation covering any therapeutically active dose.
      • Evidence for a Narrower Interpretation: The patent provides more specific dosage levels for tablets, "particularly 1.0, 5.0, 10.0, 15.0, 20.0, 25.0, 50.0," and other values up to 1000.0 milligrams '883 Patent, col. 19:8-14 A party may argue that these enumerated examples limit the scope of "an effective amount" to these specific quantities or ranges.

VI. Other Allegations

  • Indirect Infringement: Plaintiffs allege that MSN will actively induce infringement of the '883 patent, asserting that MSN has knowledge of the patent and specific intent to infringe, as evidenced by its proposed product labeling which will direct users to perform the patented method Compl. ¶59 The complaint also alleges that MSN's product is not suitable for substantial non-infringing use, forming the basis for claims of contributory infringement of both patents Compl. ¶36 Compl. ¶56
  • Willful Infringement: The complaint alleges that MSN's infringement has been and will be willful based on its knowledge of the patents-in-suit, which was established at least as of the date of its notice letter Compl. ¶40 Compl. ¶60

VII. Analyst's Conclusion: Key Questions for the Case

  • A central issue for both patents will be one of validity: can MSN demonstrate by clear and convincing evidence that the asserted claims, which were examined and allowed by the USPTO, are nonetheless invalid over the prior art?
  • A key evidentiary question for the '883 patent will be one of induced infringement: does the specific language of MSN's proposed product label inevitably instruct or encourage medical professionals and patients to administer the generic product in a manner that performs every step of the patented method for treating hypertrophic cardiomyopathy, as that method is defined by the court?
  • A nuanced validity question specific to the RE'050 patent will be the doctrine of reissue recapture: does the asserted claim 20 of the reissue patent impermissibly attempt to reclaim subject matter that was surrendered to the USPTO during the prosecution of the original patent from which it was reissued?
Loading Complaint